Nymox Pharmaceutical Corp. NYMX
We certainly hope our readers read over yesterday’s morning report thoroughly, because it would mean that people caught our closing note on NYMX in the extended watchlist. We mentioned the big gap-down on the stock, and that we’d be on the lookout for a reversal.
It didn’t take any time at all for NYMX to behave according to our suspicions; it opened at a low of .59 and immediately began its recovery, which lasted for a good portion of the day and culminated in a high of 1.03. Big congratulations are in order for anyone that took advantage of that 74% intraday rip.
The huge gap-down was apparently caused from a knee-jerk reaction to Sunday’s announcement that the company’s prostate cancer treatment (NX-1207) failed to meet primary efficacy endpoints in Phase 3 studies.
It’s fair to mention that prior to yesterday’s session, NYMX was trading at a base level just below $5 (50DMA of 4.77) and yesterday’s bottom-bounce carried it back up to a mere fraction of that level, so it will be interesting to see how much of its lost ground could potentially be recovered in coming sessions.
Labor Smart Inc. LTNC
We caught LTNC on a routine news scan this morning, and we really like what we learned from a quick glance at the PR. LTNC announced that its October revenues set a company record ($2.7M), contributed to a 23-month streak of year-over-year increases, and brought total revenue for 2014 over the $20M-mark.
- Labor SMART, Inc Reports Largest Monthly Revenue in Its History (Tue 8:38AM EST)
Those highlights are substantial enough to have us put LTNC on our radar moving forward. A company exhibiting growth patterns like these is certainly worth watching.
The chart is also coming off of a relative bottom, so it could be that we’ve stumbled across LTNC at just the right time.
Extended Watchlist:
CDTI, CDVI, ODP, VSR, MWW, FCEL